SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cadila Healthcare trades higher on the BSE

09 Nov 2021 Evaluate

Cadila Healthcare is currently trading at Rs. 497.15, up by 2.55 points or 0.52% from its previous closing of Rs. 494.60 on the BSE.

The scrip opened at Rs. 507.00 and has touched a high and low of Rs. 510.00 and Rs. 494.05 respectively. So far 140855 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 673.70 on 12-May-2021 and a 52 week low of Rs. 406.40 on 10-Nov-2020.

Last one week high and low of the scrip stood at Rs. 510.00 and Rs. 486.10 respectively. The current market cap of the company is Rs. 50777.63 crore.

The promoters holding in the company stood at 74.88%, while Institutions and Non-Institutions held 15.43% and 9.69% respectively.

Zydus Cadila has received an order to supply 1 crore doses of ZyCoV-D, the world's first Plasmid DNA Vaccine, to the Government of India at Rs 265 per dose and the needle-free applicator being offered at Rs 93 per dose, excluding GST. The pricing has been decided in consultation with the central government.

The vaccine will be administered using a needle-free applicator as opposed to traditional syringes. The applicator is called PharmaJet. The PharmaJet is a needle-free applicator to ensure painless intradermal vaccine delivery which also leads to a significant reduction in any kind of major side effects.

Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.

Zydus Lifesciences Share Price

891.65 -18.75 (-2.06%)
30-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1808.20
Dr. Reddys Lab 1322.95
Cipla 1309.90
Zydus Lifesciences 891.65
Lupin 2303.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×